LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 8 of total 8

Search options

  1. Article ; Online: Characteristic distribution of maculopapular rash caused by gemcitabine-based chemotherapy.

    Tohyama, Mikiko / Asagi, Akinori / Nakasya, Akio / Iuchi, Shunsuke / Hashine, Katsuyoshi

    The Journal of dermatology

    2020  Volume 48, Issue 2, Page(s) 215–218

    Abstract: Skin toxicity induced by gemcitabine, a chemotherapeutic agent, is not rare, but is usually mild. However, the occurrence of moderate to severe skin rash has been reported in patients treated with combinations of gemcitabine and other anticancer drugs. ... ...

    Abstract Skin toxicity induced by gemcitabine, a chemotherapeutic agent, is not rare, but is usually mild. However, the occurrence of moderate to severe skin rash has been reported in patients treated with combinations of gemcitabine and other anticancer drugs. The aim of this study was to assess the characteristics of rash caused by gemcitabine-based chemotherapy. We analyzed 12 patients who developed maculopapular rash over more than 10% of their body surface following gemcitabine-based chemotherapy. Maculopapular rash appeared at 6.3 ± 1.3 days after the first administration in eight patients and the second administration in four patients. In two patients, the rash was localized on the lateral aspect of the trunk. The other 10 patients showed various degrees of rash on the chest and abdomen, in addition to the lateral aspect of the trunk. However, rash was absent on the upper and middle back in almost all patients. After the rash disappeared, gemcitabine was re-administrated in eight patients. They continued the therapy with no or only mild rash relapse. In conclusion, maculopapular rash caused by gemcitabine-based chemotherapy shows biased distribution to frontal and lateral sites of the trunk, which may be informative for consecutive chemotherapy.
    MeSH term(s) Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Deoxycytidine/adverse effects ; Deoxycytidine/analogs & derivatives ; Drug Administration Schedule ; Exanthema/chemically induced ; Exanthema/diagnosis ; Humans
    Chemical Substances Deoxycytidine (0W860991D6) ; gemcitabine (B76N6SBZ8R)
    Language English
    Publishing date 2020-11-11
    Publishing country England
    Document type Journal Article
    ZDB-ID 800103-0
    ISSN 1346-8138 ; 0385-2407
    ISSN (online) 1346-8138
    ISSN 0385-2407
    DOI 10.1111/1346-8138.15654
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 1950: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: An exploration of trifluridine/tipiracil in combination with irinotecan in patients with pretreated advanced gastric cancer.

    Mizukami, Takuro / Minashi, Keiko / Hara, Hiroki / Nishina, Tomohiro / Amanuma, Yusuke / Takahashi, Naoki / Nakasya, Akio / Takahashi, Masaki / Nakajima, Takako Eguchi

    Investigational new drugs

    2022  Volume 40, Issue 3, Page(s) 614–621

    Abstract: Background: Trifluridine/tipiracil (FTD/TPI) and irinotecan are treatment options for heavily pretreated patients with advanced gastric cancer, but their efficacies are limited. We investigated the combination of FTD/TPI and irinotecan for such patients. ...

    Abstract Background: Trifluridine/tipiracil (FTD/TPI) and irinotecan are treatment options for heavily pretreated patients with advanced gastric cancer, but their efficacies are limited. We investigated the combination of FTD/TPI and irinotecan for such patients.
    Methods: Patients who were refractory to fluoropyrimidine, platinum and taxane were enrolled into four cohorts (Level 1A/1B/2A/2B) and treated with irinotecan (100 [Level 1] or 125 [Level 2] mg/m
    Results: Eleven patients were enrolled: 2 at Level 1A, 3 at Level 1B, and 6 at Level 2B. DLTs occurred in 2/2 patients at Level 1A and 2/6 patients at Level 2B. Grade 3 or higher treatment-related adverse events were neutropenia (90.9%), leukopenia (54.5%), anemia (45.5%) and febrile neutropenia (18.2%). One patient at Level 2B achieved a partial response, and the DCR was 72.7% (95% CI, 39.0%-94.0%). The median progression-free survival and overall survival periods were 3.0 months (95% CI, 0.92-not reached) and 10.2 months (95% CI, 2.2-not reached), respectively.
    Conclusion: The RP2D of FTD/TPI combined with irinotecan was determined to be Level 1B; this level was associated with manageable hematologic toxicities and feasible non-hematologic toxicities. Further evaluation of the efficacy of RP2D treatment is necessary.
    MeSH term(s) Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Colorectal Neoplasms/drug therapy ; Drug Combinations ; Frontotemporal Dementia/chemically induced ; Frontotemporal Dementia/drug therapy ; Humans ; Irinotecan/therapeutic use ; Pyrrolidines ; Stomach Neoplasms/drug therapy ; Stomach Neoplasms/etiology ; Thymine ; Trifluridine/adverse effects
    Chemical Substances Drug Combinations ; Pyrrolidines ; Irinotecan (7673326042) ; tipiracil (NGO10K751P) ; Thymine (QR26YLT7LT) ; Trifluridine (RMW9V5RW38)
    Language English
    Publishing date 2022-03-12
    Publishing country United States
    Document type Clinical Trial ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 604895-x
    ISSN 1573-0646 ; 0167-6997
    ISSN (online) 1573-0646
    ISSN 0167-6997
    DOI 10.1007/s10637-022-01223-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1823: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Nanoparticle albumin-bound paclitaxel and ramucirumab versus paclitaxel and ramucirumab as second-line chemotherapy for unresectable advanced or recurrent gastric cancer: a multicenter, propensity score-matched analysis (CROSS SELL study).

    Nakasya, Akio / Hagiwara, Yuya / Ikoma, Tatsuki / Kurioka, Yusuke / Matsumoto, Toshihiko / Yamamoto, Yoshiyuki / Tsuduki, Takao / Kajiwara, Takeshi / Moriwaki, Toshikazu / Nishina, Tomohiro / Yamashita, Natsumi / Hyodo, Ichinosuke

    International journal of clinical oncology

    2022  Volume 27, Issue 4, Page(s) 684–694

    Abstract: Background: Paclitaxel plus ramucirumab (PTX + RAM) is the standard second-line chemotherapy for unresectable advanced or recurrent gastric cancer (AGC). Nanoparticle albumin-bound paclitaxel (nab-PTX) is an improved, more convenient form of PTX and is ... ...

    Abstract Background: Paclitaxel plus ramucirumab (PTX + RAM) is the standard second-line chemotherapy for unresectable advanced or recurrent gastric cancer (AGC). Nanoparticle albumin-bound paclitaxel (nab-PTX) is an improved, more convenient form of PTX and is non-inferior to PTX. Although some retrospective and single-arm phase II studies regarding nab-PTX + RAM have been reported, comparative studies are lacking. Here, we compared the efficacy and toxicity of nab-PTX + RAM and PTX + RAM using propensity score matching.
    Methods: Clinical data of 265 patients treated for AGC with nab-PTX + RAM or PTX + RAM were retrospectively collected. Nab-PTX was administered at dosages of 100 mg/m
    Results: In total, 190 (72%) patients were matched. The median PFS was 5.3 [95% confidence interval (CI) 4.4-6.3] and 4.7 (95% CI 3.2-5.3) months in the nab-PTX + RAM and PTX + RAM groups, respectively [hazard ratio (HR) = 0.76, 95% CI 0.56-1.03, p = 0.07]. The median OS was 11.5 (95% CI 9.2-15.0) and 9.9 (95% CI 8.0-12.7) months, respectively (HR = 0.78, 95% CI 0.56-1.07, p = 0.12). Grade 3 and 4 neutropenia was observed more frequently in the nab-PTX + RAM group (72% vs. 56%, p = 0.03). No treatment-related deaths occurred.
    Conclusions: Nab-PTX + RAM exhibited more favorable trends in terms of PFS and OS but was more myelosuppressive than PTX + RAM. As neutropenia is commonly manageable toxicity, nab-PTX + RAM presents a treatment alternative for AGC. Further studies including randomized, controlled studies are warranted.
    MeSH term(s) Albumin-Bound Paclitaxel/therapeutic use ; Antibodies, Monoclonal, Humanized ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Humans ; Nanoparticles ; Neoplasm Recurrence, Local/etiology ; Paclitaxel ; Propensity Score ; Retrospective Studies ; Stomach Neoplasms/drug therapy ; Treatment Outcome ; Ramucirumab
    Chemical Substances Albumin-Bound Paclitaxel ; Antibodies, Monoclonal, Humanized ; Paclitaxel (P88XT4IS4D)
    Language English
    Publishing date 2022-01-28
    Publishing country Japan
    Document type Journal Article ; Multicenter Study
    ZDB-ID 1400227-9
    ISSN 1437-7772 ; 1341-9625
    ISSN (online) 1437-7772
    ISSN 1341-9625
    DOI 10.1007/s10147-022-02114-y
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4828: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article: [Tolerability of Definitive Chemoradiotherapy in Elderly Patients with Esophageal Cancer].

    Hino, Kaori / Kajiwara, Takeshi / Nishina, Tomohiro / Inoue, Tomonori / Yoshimatsu, Megumi / Sakaguchi, Chihiro / Nakasya, Akio / Nishide, Norifumi / Asagi, Akinori / Hasebe, Aki / Terao, Takashi / Hori, Shinichiro / Nadano, Seijin / Hamamoto, Yasushi / Kataoka, Masaaki / Tanimizu, Masahito

    Gan to kagaku ryoho. Cancer & chemotherapy

    2020  Volume 47, Issue 11, Page(s) 1577–1581

    Abstract: Definitive chemoradiotherapy(CRT)for esophageal cancer is the standard treatment and alternative to surgery. However, the tolerability of CRT in elderly patients is not well known. In this study, we retrospectively analyzed 60 patients with esophageal ... ...

    Abstract Definitive chemoradiotherapy(CRT)for esophageal cancer is the standard treatment and alternative to surgery. However, the tolerability of CRT in elderly patients is not well known. In this study, we retrospectively analyzed 60 patients with esophageal cancer who were treated with CRT(5-FU 700 mg/m2, cisplatin 70 mg/m2, radiation 60 Gy)at our hospital between January 2015 and September 2017. The patients were divided into 2 groups: an elderly group comprising 16 patients aged >75 years and a non-elderly group comprising 44 patients aged <74 years. The relative dose intensity of cisplatin in the elderly group was significantly lower than that in the non-elderly group. Radiotherapy was successfully executed in both groups. More patients in the elderly(25%)than the non-elderly group(7%)developed pneumonitis, and all patients who developed severe pneumonitis in the elderly group died. Application of definitive CRT and irradiation methods in elderly patients with a subpleural reticular shadow should be carefully considered before initiating therapy.
    MeSH term(s) Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Carcinoma, Squamous Cell/drug therapy ; Chemoradiotherapy/adverse effects ; Cisplatin/adverse effects ; Esophageal Neoplasms/pathology ; Fluorouracil/therapeutic use ; Humans ; Middle Aged ; Neoplasm Staging ; Patients ; Retrospective Studies ; Treatment Outcome
    Chemical Substances Cisplatin (Q20Q21Q62J) ; Fluorouracil (U3P01618RT)
    Language Japanese
    Publishing date 2020-12-02
    Publishing country Japan
    Document type Journal Article
    ZDB-ID 604842-0
    ISSN 0385-0684
    ISSN 0385-0684
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 2573: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Clinical Outcomes of S-1 Monotherapy and Modified FOLFIRINOX Therapy after Gemcitabine plus Nab-paclitaxel Therapy in Unresectable Pancreatic Cancer.

    Hino, Kaori / Nishina, Tomohiro / Numata, Yuuki / Asagi, Akinori / Inoue, Tomonori / Yoshimatsu, Megumi / Sakaguchi, Chihiro / Nakasya, Akio / Nishide, Norifumi / Kajiwara, Takeshi / Terao, Takashi / Nadano, Seijin / Marui, Kaori / Okujima, Yusuke / Kokubu, Masahito / Imamura, Yoshiki / Kanemitsu, Kozue / Koizumi, Mitsuhito / Kumagi, Teru /
    Hiasa, Yoichi / Hyodo, Ichinosuke

    Internal medicine (Tokyo, Japan)

    2022  Volume 61, Issue 15, Page(s) 2255–2261

    Abstract: Objective S-1 and modified FOLFIRINOX (mFFX) were often used as the second-line chemotherapies after failure of gemcitabine plus nab-paclitaxel (GnP) in unresectable pancreatic cancer (UPC) until nanoliposomal irinotecan plus 5-fluorouracil/leucovorin ... ...

    Abstract Objective S-1 and modified FOLFIRINOX (mFFX) were often used as the second-line chemotherapies after failure of gemcitabine plus nab-paclitaxel (GnP) in unresectable pancreatic cancer (UPC) until nanoliposomal irinotecan plus 5-fluorouracil/leucovorin therapy was approved as an alternative in Japan in 2020. However, the clinical outcomes of S-1 and mFFX after GnP have scarcely been reported. Therefore, we retrospectively studied them. Methods We extracted the clinical data of 86 patients with UPC who received second-line chemotherapy after GnP between 2015 and 2020. Among the patients who had a good organ functions and no massive ascites, 41 patients treated with S-1 and 21 treated with mFFX were enrolled. Results Compared to S-1, mFFX tended to be used for younger patients with a good general condition (median age, 63 vs. 71 years, p<0.01; and performance status 0, 67% vs. 37%, p<0.05). The median progression-free and overall survival were similar between the S-1 (3.7 and 7.2 months, respectively) and mFFX (3.3 and 7.4 months, respectively) groups. The response rate in patients with measurable lesions was 4% (n=1/23) in the S-1 group and 17% (n=2/12) in the mFFX group. The incidence of grade 3 or 4 adverse events was 20% in the S-1 group and 57% (neutrophil count decreased in 43%) in the mFFX group (p<0.01). Conclusion S-1 and mFFX were both acceptable second-line chemotherapies after GnP therapy for UPC, although attention should be paid to myelosuppression during mFFX treatment. Further studies involving nanoliposomal irinotecan plus 5-fluorouracil/leucovorin therapy are necessary to facilitate the selection of the optimal regimen for each patient.
    MeSH term(s) Albumins/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Deoxycytidine/analogs & derivatives ; Fluorouracil ; Humans ; Irinotecan/adverse effects ; Leucovorin/adverse effects ; Middle Aged ; Oxaliplatin ; Paclitaxel/therapeutic use ; Pancreatic Neoplasms/pathology ; Retrospective Studies ; Gemcitabine ; Pancreatic Neoplasms
    Chemical Substances 130-nm albumin-bound paclitaxel ; Albumins ; folfirinox ; Oxaliplatin (04ZR38536J) ; Deoxycytidine (0W860991D6) ; Irinotecan (7673326042) ; Paclitaxel (P88XT4IS4D) ; Leucovorin (Q573I9DVLP) ; Fluorouracil (U3P01618RT) ; Gemcitabine
    Language English
    Publishing date 2022-08-01
    Publishing country Japan
    Document type Journal Article
    ZDB-ID 32371-8
    ISSN 1349-7235 ; 0021-5120 ; 0918-2918
    ISSN (online) 1349-7235
    ISSN 0021-5120 ; 0918-2918
    DOI 10.2169/internalmedicine.8736-21
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 240: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: A case of bleeding duodenal ulcer with pemphigus vulgaris during steroid therapy.

    Niho, Kojiro / Nakasya, Akio / Ijichi, Ayako / Tsujita, Jun / Gotoh, Kazuhito / Shinozaki, Hirotsugu / Matsumoto, Masahiro

    Clinical journal of gastroenterology

    2014  Volume 7, Issue 3, Page(s) 223–227

    Abstract: We report a rare case of bleeding duodenal ulceration in the different form of pemphigus vulgaris (PV). A 52-year-old female was diagnosed with acute pharyngitis and administered methylprednisolone. After several days, melena and many blisters were noted ...

    Abstract We report a rare case of bleeding duodenal ulceration in the different form of pemphigus vulgaris (PV). A 52-year-old female was diagnosed with acute pharyngitis and administered methylprednisolone. After several days, melena and many blisters were noted on her body. Endoscopy revealed blood oozing from the second part of a duodeneal ulcer around the major duodenal papilla. After initial endoscopic hemostasis, we observed a large regional, shallow duodenal ulcer. The blisters were suspected to represent the Nikolsky's sign. The histological findings of her skin were characterized by suprabasal acantholysis and mixed inflammatory cell infiltrates, including scattered eosinophils. There were no other significant findings on skin biopsy or by direct immunofluorescence. Enzyme-linked immunosorbent assay showed an elevated titer of anti-desmoglein 3 autoantibodies in her serum, and the patient was finally diagnosed with mucosal-dominant PV. Although we performed multiple biopsies from the esophagus, stomach and duodenum, the samples did not contain significant findings to enable us to distinguish from pemphigus vulgaris. Corticosteroids remain an essential component of PV treatment. When clinicians encounter PV development during steroid therapy, upper gastrointestinal complications should be considered and diagnostic endoscopy conducted.
    MeSH term(s) Duodenal Ulcer/chemically induced ; Female ; Glucocorticoids/adverse effects ; Humans ; Methylprednisolone/adverse effects ; Middle Aged ; Pemphigus/chemically induced ; Peptic Ulcer Hemorrhage/chemically induced
    Chemical Substances Glucocorticoids ; Methylprednisolone (X4W7ZR7023)
    Language English
    Publishing date 2014-06
    Publishing country Japan
    Document type Case Reports ; Journal Article
    ZDB-ID 2429411-1
    ISSN 1865-7265 ; 1865-7257
    ISSN (online) 1865-7265
    ISSN 1865-7257
    DOI 10.1007/s12328-014-0476-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: NOTCH gene alterations in metastatic colorectal cancer in the Nationwide Cancer Genome Screening Project in Japan (SCRUM-Japan GI-SCREEN).

    Kajiwara, Takeshi / Nishina, Tomohiro / Nakasya, Akio / Yamashita, Natsumi / Yamashita, Riu / Nakamura, Yoshiaki / Shiozawa, Manabu / Yuki, Satoshi / Taniguchi, Hiroya / Hara, Hiroki / Ohta, Takashi / Esaki, Taito / Shinozaki, Eiji / Takashima, Atsuo / Moriwaki, Toshikazu / Denda, Tadamichi / Ohtsubo, Koushiro / Sunakawa, Yu / Horita, Yosuke /
    Kawakami, Hisato / Kato, Takeshi / Satoh, Taroh / Ando, Koji / Mizutani, Tomonori / Yasui, Hisateru / Goto, Masahiro / Okuyama, Hiroyuki / Yamazaki, Kentaro / Yoshino, Takayuki / Hyodo, Ichinosuke

    Journal of cancer research and clinical oncology

    2022  Volume 148, Issue 10, Page(s) 2841–2854

    Abstract: Purpose: Activated Notch receptor signaling has been implicated in tumor growth and progression in colorectal cancer (CRC). However, the pathogenic relevance of NOTCH gene alterations remains unclear. The aim of this study was to clarify mutational ... ...

    Abstract Purpose: Activated Notch receptor signaling has been implicated in tumor growth and progression in colorectal cancer (CRC). However, the pathogenic relevance of NOTCH gene alterations remains unclear. The aim of this study was to clarify mutational landscapes and assess their clinical significance in patients with metastatic CRC.
    Methods: Pre-chemotherapy tumor tissues obtained from 1154 metastatic CRC patients in the Nationwide Cancer Genome Screening Project in Japan between April 2017 and March 2019 were studied using the Oncomine Comprehensive Assay.
    Results: The frequencies of NOTCH1, NOTCH2, and NOTCH3 nonsynonymous sequence variants were 11.5%, 4.4%, and 10.4%, respectively. The majority of variants were missense of unknown significance that were distributed across all domains of all three NOTCH genes. The gain-of-function mutations in NOTCH reported in multiple malignancies were not identified. The NOTCH amplification rate was less than 1%. No NOTCH fusions were detected. In patients who were registered before, or within 1 year of, first-line chemotherapy, overall survival for 51 patients with only NOTCH3 variants was significantly longer than for 540 patients with no NOTCH variants (median, 40.2 months vs 27.7 months; P = 0.04). Multivariate analysis revealed that variant NOTCH3 was an independent prognostic factor for increased survival (hazard ratio 0.61, 95% confidence interval, 0.39-0.94; P = 0.03) besides poor prognostic factors associated with mutant TP53, KRAS, and BRAF, as well as amplified MYC.
    Conclusion: NOTCH genes are unlikely to harbor driver mutations and amplifications in patients with metastatic CRC. NOTCH3 variant should be further investigated as a favorable prognostic marker.
    MeSH term(s) Colonic Neoplasms ; Colorectal Neoplasms/drug therapy ; Colorectal Neoplasms/genetics ; Colorectal Neoplasms/pathology ; Early Detection of Cancer ; Humans ; Japan ; Mutation ; Prognosis ; Rectal Neoplasms ; Signal Transduction/genetics
    Language English
    Publishing date 2022-05-27
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 134792-5
    ISSN 1432-1335 ; 0171-5216 ; 0084-5353 ; 0943-9382
    ISSN (online) 1432-1335
    ISSN 0171-5216 ; 0084-5353 ; 0943-9382
    DOI 10.1007/s00432-022-04064-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.10: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article: [A case of hepatocellular carcinoma with respiratory failure caused by widespread tumor microemboli].

    Tanaka, Kosuke / Nakasya, Akio / Miyazaki, Masanori / Takao, Shinichiro / Higuchi, Nobito / Tanaka, Masatake / Tanaka, Yuki / Kato, Masaki / Kato, Kazuhiro / Takayanagi, Ryoichi / Aishima, Shinichi

    Fukuoka igaku zasshi = Hukuoka acta medica

    2011  Volume 102, Issue 10, Page(s) 298–302

    Abstract: A 76-year-old man with hepatocellular carcinoma (HCC) was admitted to our hospital suffering from rapidly progressing dyspnea. Chest computed tomography on admission merely showed ground-glass patterns in both lung fields without thrombi in the pulmonary ...

    Abstract A 76-year-old man with hepatocellular carcinoma (HCC) was admitted to our hospital suffering from rapidly progressing dyspnea. Chest computed tomography on admission merely showed ground-glass patterns in both lung fields without thrombi in the pulmonary trunk. On the third day, pulmonary blood flow scintigraphy was performed because of progression of his dyspnea, and showed multiple defects indicating widespread thrombi in the peripheral pulmonary arteries. He died of respiratory failure on day 13. A needle necropsy revealed the presence of multiple foci of adenocarcinoma nests in the lungs, suggesting venous thrombi from the poorly differentiated HCC. Although HCC frequently metastasizes to the lung, patients with lung metastasis rarely result in respiratory failure. It is well known that some patients with adenocarcinoma including HCC can develop respiratory failure owing to pulmonary tumor thrombotic microangiopathy (PTTM). In our case, however, pathological examination showed widespread tumor microemboli in the lung, but no stenosis or fibrocellular intimal proliferation in the small arteries and arterioles, which are essential findings of PTTM. Although we concluded that the respiratory failure in this case was mainly caused by widespread tumor microemboli, it remains unclear why such dissemination rapidly developed.
    MeSH term(s) Aged ; Carcinoma, Hepatocellular/pathology ; Humans ; Liver Neoplasms/pathology ; Lung Neoplasms/secondary ; Male ; Neoplastic Cells, Circulating/pathology ; Respiratory Insufficiency/etiology
    Language Japanese
    Publishing date 2011-10
    Publishing country Japan
    Document type Case Reports ; English Abstract ; Journal Article
    ZDB-ID 41251-x
    ISSN 0016-254X
    ISSN 0016-254X
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 124: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top